GENEVA, July 31 -- ATEA PHARMACEUTICALS, INC. filed a patent application (US2026/012199) for “ADVANTAGEOUS FIXED-DOSE COMBINATION TREATMENT FOR HCV INFECTION”. With publication no. WO/2026/161597, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: A61K 31/675
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....